The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

Clinical Roundup

TriSalus, UColorado Anschutz Medical Campus to collaborate on immuno-oncology treatments for liver and pancreatic tumors

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

TriSalus Life Sciences and the University of Colorado Anschutz Medical Campus entered a strategic research collaboration to advance research of immuno-oncology treatments for patients with liver and pancreatic tumors. 

Over the next three years, TriSalus will collaborate with the University of Colorado Anschutz Medical Campus on studies using TriSalus’ proprietary Pressure-Enabled Drug Delivery (PEDD) method for the administration of an investigational toll-like receptor 9 (TLR9) agonist, SD-101.

TriSalus’ platform consists of an investigational immunotherapy, SD-101, that aims to reactivate the immune system within these organs for targeted tumor killing, and the PEDD method, which modulates pressure and flow within blood vessels to improve therapy uptake and tumor response.

CU Innovations has led the establishment of the business relationship while the CU Anschutz research team will focus on creating clinical research to advance TriSalus’ approach.  

Table of Contents

YOU MAY BE INTERESTED IN

Clinical Roundup

Immunity against CMV leveraged against pancreatic cancer in study by UCSD, La Jolla Institute of Immunology

Researchers at the University of California San Diego and La Jolla Institute of Immunology have discovered a promising treatment approach for pancreatic cancer, one of the deadliest and most treatment-resistant forms of cancer. The approach leverages the body’s natural immune response to cytomegalovirus, a common but typically harmless virus that most people are infected with at some point in their lives. 
Drugs & Targets

HanchorBio and WuXi Biologics form partnership to advance next-generation bi-and multi-functional fusion protein pipeline

HanchorBio, a global clinical-stage biotechnology company, and WuXi Biologics, a global Contract Research, Development, and Manufacturing Organization, jointly announced the signing of a strategic collaboration agreement to support the development and manufacturing of multiple next-generation bi- and multi-functional fusion programs from HanchorBio’s pipeline.
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account